A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Inclusion Criteria:

- Have a diagnosis of cancer that is advanced and/or metastatic.

- Have disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST )
version 1.1.

- Have adequate organ function.

- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Have discontinued previous treatments for cancer for at least 28 days or 5 half-lives
prior to study enrolment.

Exclusion Criteria:

- Have serious preexisting medical conditions.

- Have received treatment with a drug predominantly targeting Ang2 activity.

- Have symptomatic central nervous system (CNS) malignancy or metastasis.

- Have current hematologic malignancies.

- Have an active fungal, bacterial, and/or known viral infection.

- Have a corrected QT interval using Fridericia's correction (QTcF) of >470 msec on
screening electrocardiogram (ECG) at several consecutive days of assessment.

- Have a known sensitivity to mAbs or other therapeutic proteins.

- Have a history of hypertensive crisis or hypertensive encephalopathy or current poorly
controlled hypertension despite standard medical management.

- Have a significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode
within 3 months prior to receiving treatment.

- Receive anticoagulation therapy at therapeutic dose.

- Have experienced any arterial or venothrombotic or thromboembolic events within 6
months prior to study treatment.

- Have liver cirrhosis with a Child-Pugh class B or worse or cirrhosis (any degree) and
a history of hepatic encephalopathy or clinically meaningful ascites resulting from
cirrhosis.

- The participant is pregnant prior to randomization or breastfeeding.

- The participant has sensory peripheral neuropathy ≥ Grade 2 (Part E only).